BURGEON X VIVACY SIGN STRATEGIC ALLIANCE

Ankara, March 26, 2025– Burgeon Biotechnology, an Ankara-based Turkish biotech company developing innovative and sustainable solutions for all skin types, and Laboratoires VIVACY, a Paris-based French leader in injectable products for healthcare professionals, have signed a strategic collaboration that brings together the innovative technology of NOVUMA® calcium hydroxyapatite (CaHA) biostimulator with the scientific expertise of STYLAGE® hyaluronic acid (HA)-based dermal fillers. This powerful synergy, born from the integration of two advanced technology platforms, aims to significantly contribute to meeting the evolving needs of patients by equipping experts worldwide with scientifically innovative and clinically proven solutions that deliver superior efficacy in skin rejuvenation.

Shared vision: Redefining the field of regenerative aesthetics

Levent Mete Özgürbüz, Founder and Managing Partner of Burgeon Biotechnology, said:

“Thanks to our innovative technologies, pioneering vision, and proven global success, we have established a strategic partnership with VIVACY, a prominent player in the industry. We are thrilled to have signed a significant global collaboration that reflects the value we create and the strength of our groundbreaking technologies. Through this partnership, we will continue to lead the industry and deliver innovative solutions. Together with VIVACY, we will break new ground, develop future-defining solutions, and achieve global success.”

“NOVUMA represents a significant opportunity for VIVACY to enter the rapidly growing biostimulator market,” said Bertrand Frohly, President and CEO of Laboratoires VIVACY :

“NOVUMA directly addresses the growing consumer demand for skin quality and rejuvenation. It perfectly complements our existing STYLAGE® hyaluronic acid (HA) portfolio, where we maintain a leading position in Europe. In the coming months, we will launch NOVUMA first in Europe, followed by other regions. Our goal is to equip our expert partners with the most advanced technologies to safely and effectively meet patients’ expectations for enhancing appearance and skin quality.”

Denis Couchourel, Scientific and Medical Director of Laboratoires VIVACY, said:

“At VIVACY, scientific excellence is at the core of our innovation. By combining our expertise in hyaluronic acid with Burgeon Biotechnology’s research in calcium hydroxyapatite, we are pushing the boundaries of regenerative aesthetics and delivering next-generation injectable solutions that align with skin biology.”

Commitment to excellence in regenerative aesthetics from Burgeon and VIVACY

This collaboration reinforces the pioneering position of Burgeon Biotechnology and VIVACY in the field of medical aesthetics and advances their shared vision of delivering fast, effective, and scientifically proven solutions that support skin renewal and healthy aging at every stage of life. For more information about Burgeon Biotechnology and Laboratoires VIVACY, please visit www.burgeon.me and www.vivacy.com.

About Burgeon Biotechnology

Burgeon Biotechnology is an innovative biotechnology company that develops, manufactures and globally distributes advanced biostimulatory dermal fillers and aesthetic solutions. Founded in 2017, Burgeon, with a vision to redefine the concept of beauty with its scientifically proven and transformative products, has quickly a globally recognized leader in biostimulation technology has become. Burgeon is internationally recognized for NOVUMA, a new generation biostimulator with Calcium Hydroxyapatite (CaHA), specially developed to reverse the visible signs of aging: wrinkles, dry skin and sagging. Increasing global demand for aesthetic solutions In response, Burgeon Biotechnology has launched CALHYDRA, a rapidly popular hybrid dermal filler application kit. Burgeon Biotechnology, focusing on the field of biostimulation, exports its innovative products to more than 45 countries covering Latin America, Asia-Pacific, the Middle East and Europe. Continuously expanding its global operations, the company has earned the trust of aestheticians around the world by offering safe, effective and pioneering solutions. Committed to excellence, sustainability and continuous technological development, Burgeon Biotechnology continues to reshape the concept of aesthetics, enabling individuals around the world to gain self-confidence through natural beauty. 

About VIVACY

Laboratoires VIVACY is a French manufacturer specialized in the development, production and distribution of premium quality, hyaluronic acid-based medical devices in the field of aesthetic and anti-aging medicine. Founded in 2007, VIVACY has become one of the leading companies in aesthetic medicine with its innovative approach in the field of biotechnology with 15 patent families. The company is known for its STYLAGE® brand of high-quality, pharmaceutical-grade hyaluronic acid-based dermal fillers, produced using its unique and patented IPN-Like Technology and enriched with antioxidants, mannitol and sorbitol. The range is ideal for treating fine lines, increasing facial volume and improving skin quality. VIVACY has also developed injectable solutions such as DESIRIAL® in gynecology, I.SPACE® in ophthalmology and KARTILAGE® in rheumatology. All products are manufactured in a high-tech production facility located in Archamps Technopole near Geneva, on the French-Swiss border. VIVACY currently operates in more than 85 countries worldwide, with subsidiaries in Switzerland, the United Kingdom, Canada, Poland, Spain, Italy and Benelux, and employs more than 300 people worldwide. With a strong commitment to research, technological development and high-performance products, VIVACY remains a trusted partner for patients and aesthetic professionals worldwide.